The seco-taxane IDN5390 is able to target class III β-tubulin and to overcome paclitaxel resistance

Cancer Research

Volumn 65, Issue 6, 2005, Pages 2397-2405

  Ferlini, Cristiano ^a,b   Raspaglio, Giuseppina ^a   Mozzetti, Simona ^a   Cicchillitti, Lucia ^a   Filippetti, Flavia ^a   Gallo, Daniela ^a,b   Fattorusso, Caterina ^b,c   Campiani, Giuseppe ^b   Scambia, Giovanni ^b,d  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BETA TUBULIN; BETA TUBULIN III; BLOCKING ANTIBODY; CISPLATIN; CYCLOSPORIN A; DOXORUBICIN; IDN 5390; PACLITAXEL; SERINE; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN POLYMERIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; MODELS, MOLECULAR; PACLITAXEL; TAXOIDS; TUBULIN;

EID: 16844378550     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3065     Document Type: Article

References (32)

1. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
2. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 1993;90:9552-6.
3. Kavallaris M, Kuo DYS, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997;100:1282-93.
4. Cleveland DW, Sullivan KF. Molecular biology and genetics of tubulin. Annu Rev Biochem 1985;54:331-65.
5. Lu Q, Luduena RF. Removal of β III isotype enhances taxol induced microtubule assembly. Cell Struct Funct 1993;18:173-82.
6. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified β-tubulin isotypes. Biochemistry 1997;36:3554-62.
7. Appendino G, Danieli B, Jakupovic J, et al. Synthesis and evaluation of C-seco paclitaxel analogues. Tetrahedron Letters 1997;38:4273-6.
8. Taraboletti G, Micheletti G, Rieppi M, et al. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res 2002;8:1182-8.
9. Pratesi G, Laccabue D, Lanzi C, et al. IDN 5390: an oral taxane candidate for protracted treatment schedules. Br J Cancer 2003;88:965-72.
10. Petrangolini G, Cassinelli G, Pratesi G, et al. Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft. Br J Cancer 2004;90:1464-8.
11. Ferlini C, Raspaglio G, Mozzetti S, et al. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 2003;64:51-8.
12. Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981;35:269-335.
13. Ranganathan S, Dexter DW, Benetatos CA, et al. Increase of P(III)- and p(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 1996;56:2584-9.
14. Jordan MA, Ojima I, Rosas F, et al. Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis. Chem Biol 2002;9:93-101.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
16. Nicoletti MI, Valoti G, Giannakakou P, et al. Expression of β-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Clin Cancer Res 2001;7:2912-22.
17. Carre M, Andre N, Carles G, et al. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J Biol Chem 2002;277:33664-9.
18. Banerjee A, Roach MC, Trcka P, Luduena RF. Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of β-tubulin. J Biol Chem 1990;265:1794-9.
19. Detrich HW III, Jordan MA, Wilson L, Williams RC Jr. Mechanism of microtubule assembly. Changes in polymer structure and organization during assembly of sea urchin egg tubulin. J Biol Chem 1985;260:9479-90.
20. Lowe J, Li H, Downing KH, Nogales E. Refined structure of α β-tubulin at 3.5 A resolution. J Mol Biol 2001;313:1045-57.
21. Horwitz SB, Lothstein L, Manfradi JJ, et al. Taxol: mechanisms of action and resistance. Ann-N-Y-Acad-Sci 1986;466:733-44.
22. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxeldriven polymerization. J Biol Chem 1997;272:17118-25.
23. Kaye SB. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol 1998;10S1:S15-9.
24. Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with β-tubulin gene mutations. J Clin Oncol 1999;17:1786-93.
25. Tsurutani J, Komiya T, Uejima H, et al. Mutational analysis of the β-tubulin gene in lung cancer. Lung Cancer 2002;35:11-6.
26. Sale S, Sung R, Shen P, et al. Conservation of the class I {β}-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther 2002;1:215-25.
27. Hasegawa S, Miyoshi Y, Egawa C, et al. Prediction of response to docetaxel by quantitative analysis of class I and III β-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003;9:2992-7.
28. Panda D, Miller HP, Banerjee A, Luduena RF, Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U S A 1994;91:11358-62.
29. Burkhart CA, Kavallaris M, Band HS. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001;1471:1-9.
30. Li Y, Edsall R Jr, Jagtap PG, Kingston DG, Bane S. Equilibrium studies of a fluorescent paclitaxel derivative binding to microtubules. Biochemistry 2000;39:616-23.
31. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
32. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 2003;56:45-56.